Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy ; volume:5 ; number:1 ; day:22 ; month:6 ; year:2016 ; pages:1-11 ; date:12.2015
Experimental hematology & oncology ; 5, Heft 1 (22.6.2016), 1-11, 12.2015
- Creator
-
Pham, Thy
- Contributor
-
Sadowski, Martin C.
Li, Huika
Richard, Derek J.
d’Emden, Michael C.
Richard, Kerry
SpringerLink (Online service)
- DOI
-
10.1186/s40164-016-0046-1
- URN
-
urn:nbn:de:1111-2016062411652
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pham, Thy
- Sadowski, Martin C.
- Li, Huika
- Richard, Derek J.
- d’Emden, Michael C.
- Richard, Kerry
- SpringerLink (Online service)
Other Objects (12)
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer